about
CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatoryDistinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 studyGag-Specific CD8 T-Cell Proliferation Is Associated With Higher Peripheral Blood Levels of Transforming Growth Factor-β and Gut-Homing T Cells in Youths Perinatally Infected With Human Immunodeficiency Virus-1: The ANRS-EP38-IMMIP Study.Cis-perturbation of cancer drivers by the HTLV-1/BLV proviruses is an early determinant of leukemogenesis.Use of genotypic identification by sodA sequencing in a prospective study to examine the distribution of coagulase-negative Staphylococcus species among strains recovered during septic orthopedic surgery and evaluate their significance.New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA loadPost-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI StudyAdenoviral infection presenting as an isolated central nervous system disease without detectable viremia in two children after stem cell transplantation.Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study.Gag-Specific CD4 and CD8 T-Cell Proliferation in Adolescents and Young Adults with Perinatally Acquired HIV-1 Infection Is Associated with Ethnicity - The ANRS-EP38-IMMIP Study.Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1.Elite controllers as a model of functional cure.Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression.Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification.Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.CCR5 antagonists: a therapeutic option in HIV-1 perinatally infected children experiencing virologic failure?Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study.Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir.Gag-Specific CD4 T Cell Proliferation, Plasmacytoid Dendritic Cells, and Ethnicity in Perinatally HIV-1-Infected Youths: The ANRS-EP38-IMMIP Study.Polyfunctional HIV-specific T cells in Post-Treatment Controllers.NKG2C+ memory-like NK cells contribute to the control of HIV viremia during primary infection: Optiprim-ANRS 147.Impact of early cART on HIV blood and semen compartments at the time of primary infection.Interlaboratory quality control of total HIV-1 DNA load measurement for multicenter reservoir studies.HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.High decay of blood HIV reservoir when tenofovir/emtricitabine/elvitegravir/cobicistat is initiated during the acute primary HIV infection.Clinical severity and molecular characteristics of circulating and emerging rotaviruses in young children attending hospital emergency departments in France.HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial).Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission.HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.HIV-1 DNA concentrations and evolution among African HIV-1-infected children under antiretroviral treatment (ANRS 1244/1278).Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients.Blimp-1 overexpression is associated with low HIV-1 reservoir and transcription levels in central memory CD4+ T cells from elite controllers.Naive T lymphocytes and recent thymic emigrants are associated with HIV-1 disease history in french adolescents and young adults infected in the perinatal period: the ANRS-EP38-IMMIP study.Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123--ETOILE).Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial.Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrhea.
P50
Q28477861-FBE43592-71CB-40A2-8ECB-214758A848B8Q33395678-9CD54083-E5F9-4E37-BFFE-6351DCF697CBQ33629212-25B9F112-FBC0-4AD7-B97D-0E8489A2ACC2Q33759081-73DAE5F9-13D8-48D6-8F08-A7B5860CAC53Q33856303-F720C708-3E3D-43D3-9046-194EAF6CD703Q34058765-6B63B03A-0575-4C30-B555-FEC76F777013Q34629153-98BA0DFB-5E38-4A96-956E-8BDCE9F3082FQ35066758-FC6F36BB-8032-40A0-89F4-5ACEE5D562ECQ35683067-41C2C030-5CEB-4692-B3FB-7F5D9D067340Q35864285-8D4B934A-437E-4AFB-BB47-C12A6D42DD9CQ36525896-78AA14FE-AB5B-4A72-A3B5-719B8429BD3BQ37860878-00FAC59C-8D77-43FF-B1F1-64FBDF4C44FAQ38383070-6D347442-D1EB-4C29-94E4-68D52E4FE5CEQ38417936-D955DE77-4D53-4DB0-A85D-85C2A902E8E3Q38936786-AA950BD6-8180-4BDB-A61E-03C5A44526E7Q39010561-8D38FA65-375B-42FD-87FB-B490A72D7B32Q39036883-15D4FC76-1FDF-43F1-AB61-FB62AF94B528Q39080586-CEE243C4-5DFA-4123-A4A5-E611BD58D6F6Q39276828-2CAC0C08-9B23-4F34-874F-C220FA874EA9Q39390813-304D2CD9-29EB-4C88-A973-5255A74B60B7Q39427044-E1E831FD-A952-4E8A-B795-527A1A7C6C29Q40089883-0AB3EDEC-A875-402C-A1EF-14F162F99C5CQ40122641-DC9C0BA0-FB41-426D-85AE-D52196851AF4Q40158843-CFE6A35F-24BF-4861-A911-C58B2AB0350DQ40159913-B5A8E5E0-2502-47F9-9067-BD39B2EA03C8Q40184930-A5F8F8C2-1EF7-48A4-A322-B95092728CFEQ40707133-F3EBC117-3BEF-448C-9E55-2C3225EB56F8Q40834710-7ACA4CB2-07DB-424B-8B24-D307612C6F2EQ40909527-8AB6F093-880D-4D9F-9615-E8E2518CF735Q41299483-8005D501-FBEB-4CD4-BF01-66D707EBAC7DQ41322014-FD718A28-F02B-424C-843C-91A2BBBAAECCQ42205378-E299D02E-8647-4707-96DF-5FA9B055D040Q42208838-0E5610E7-BFC4-4159-804D-143FF8A4DF27Q42220119-2A960DB2-7356-4E65-8FF5-9C72723A3396Q42240026-EA243799-8912-41B1-8CA5-753A0F1B394BQ42953414-0290EACB-9C4F-437E-B9CC-2E4267FA4EB0Q43124622-DAF07CF4-C600-461B-97AB-B7DB4EE4BF6DQ44057677-F43C9D4C-6884-4782-AD1D-C3DFBC756773Q44886006-5F87FB2E-602B-45F9-87F8-545390131E35Q45148365-A0F495B3-8061-414D-9025-9AE69BC2DD99
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Véronique Avettand-Fenoel
@ast
Véronique Avettand-Fenoel
@en
Véronique Avettand-Fenoel
@es
Véronique Avettand-Fenoel
@nl
Véronique Avettand-Fenoel
@sl
type
label
Véronique Avettand-Fenoel
@ast
Véronique Avettand-Fenoel
@en
Véronique Avettand-Fenoel
@es
Véronique Avettand-Fenoel
@nl
Véronique Avettand-Fenoel
@sl
prefLabel
Véronique Avettand-Fenoel
@ast
Véronique Avettand-Fenoel
@en
Véronique Avettand-Fenoel
@es
Véronique Avettand-Fenoel
@nl
Véronique Avettand-Fenoel
@sl
P1053
O-6285-2017
P106
P1153
35313349500
P21
P31
P3829
P496
0000-0002-7022-2990